Fonar (FONR) Competitors $16.00 +0.08 (+0.50%) Closing price 04:00 PM EasternExtended Trading$16.13 +0.13 (+0.81%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock FONR vs. TMCI, OM, CLPT, RXST, NPCE, SNWV, NNOX, CATX, DRTS, and NYXHShould you be buying Fonar stock or one of its competitors? The main competitors of Fonar include Treace Medical Concepts (TMCI), Outset Medical (OM), ClearPoint Neuro (CLPT), RxSight (RXST), NeuroPace (NPCE), Sanuwave Health (SNWV), Nano-X Imaging (NNOX), Perspective Therapeutics (CATX), Alpha Tau Medical (DRTS), and Nyxoah (NYXH). These companies are all part of the "medical equipment" industry. Fonar vs. Its Competitors Treace Medical Concepts Outset Medical ClearPoint Neuro RxSight NeuroPace Sanuwave Health Nano-X Imaging Perspective Therapeutics Alpha Tau Medical Nyxoah Treace Medical Concepts (NASDAQ:TMCI) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability. Which has higher valuation and earnings, TMCI or FONR? Fonar has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTreace Medical Concepts$209.36M1.70-$55.74M-$0.85-6.65Fonar$102.88M0.96$10.57M$1.2512.80 Do institutionals and insiders have more ownership in TMCI or FONR? 84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 50.6% of Fonar shares are held by institutional investors. 27.7% of Treace Medical Concepts shares are held by company insiders. Comparatively, 1.6% of Fonar shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Is TMCI or FONR more profitable? Fonar has a net margin of 8.19% compared to Treace Medical Concepts' net margin of -25.14%. Fonar's return on equity of 5.31% beat Treace Medical Concepts' return on equity.Company Net Margins Return on Equity Return on Assets Treace Medical Concepts-25.14% -48.69% -24.59% Fonar 8.19%5.31%3.97% Does the media prefer TMCI or FONR? In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 1 articles in the media. Treace Medical Concepts' average media sentiment score of 1.77 beat Fonar's score of 0.62 indicating that Treace Medical Concepts is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fonar 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, TMCI or FONR? Treace Medical Concepts has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, Fonar has a beta of 1, suggesting that its stock price has a similar volatility profile to the S&P 500. Do analysts prefer TMCI or FONR? Treace Medical Concepts presently has a consensus target price of $10.52, suggesting a potential upside of 86.14%. Given Treace Medical Concepts' stronger consensus rating and higher possible upside, equities analysts clearly believe Treace Medical Concepts is more favorable than Fonar.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Treace Medical Concepts 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Fonar 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryTreace Medical Concepts beats Fonar on 8 of the 15 factors compared between the two stocks. Get Fonar News Delivered to You Automatically Sign up to receive the latest news and ratings for FONR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FONR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FONR vs. The Competition Export to ExcelMetricFonarMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.76M$10.25B$5.54B$9.41BDividend YieldN/A2.06%3.75%4.03%P/E Ratio12.8011.7121.0120.09Price / Sales0.9630.03433.8199.01Price / Cash5.1722.3936.1658.27Price / Book0.653.578.125.65Net Income$10.57M$235.43M$3.25B$257.91M7 Day Performance0.95%-1.67%0.97%2.09%1 Month Performance13.80%2.91%7.36%11.13%1 Year Performance-10.46%-16.44%31.31%18.40% Fonar Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FONRFonar1.2898 of 5 stars$16.00+0.5%N/A-10.0%$98.76M$102.88M12.80480News CoverageHigh Trading VolumeTMCITreace Medical Concepts2.8658 of 5 stars$5.99-0.2%$10.52+75.6%-31.4%$376.71M$210.82M-7.05250OMOutset Medical1.463 of 5 stars$18.81-3.0%$29.50+56.8%-73.5%$333.31M$113.69M-0.65520News CoverageCLPTClearPoint Neuro1.7055 of 5 stars$11.85+3.9%$25.00+111.0%+57.0%$331.68M$31.39M-15.59110RXSTRxSight2.2718 of 5 stars$7.74-3.3%$18.44+138.3%-84.4%$314.53M$148.31M-11.55220Analyst DowngradeHigh Trading VolumeNPCENeuroPace3.5917 of 5 stars$9.55+0.3%$17.00+78.0%+20.9%$313.23M$84.31M-11.37170Positive NewsSNWVSanuwave HealthN/A$36.16+4.0%N/AN/A$309.39M$36.19M-7.9440NNOXNano-X Imaging2.2068 of 5 stars$5.15+1.8%$9.50+84.5%-40.5%$297.57M$11.28M-5.72190Positive NewsCATXPerspective Therapeutics2.3466 of 5 stars$4.00+0.5%$12.56+213.9%-65.5%$296.91MN/A0.0070DRTSAlpha Tau Medical3.1713 of 5 stars$3.23+5.6%$8.00+147.7%+45.0%$273.97MN/A-7.0280News CoverageGap UpHigh Trading VolumeNYXHNyxoah2.5681 of 5 stars$7.84+3.7%$14.50+84.9%-10.0%$267.03M$4.36M-3.68110Positive News Related Companies and Tools Related Companies Treace Medical Concepts Competitors Outset Medical Competitors ClearPoint Neuro Competitors RxSight Competitors NeuroPace Competitors Sanuwave Health Competitors Nano-X Imaging Competitors Perspective Therapeutics Competitors Alpha Tau Medical Competitors Nyxoah Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FONR) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fonar Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Fonar With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
